高级检索
当前位置: 首页 > 详情页

Construction and validation of a TP53-associated immune prognostic model for gastric cancer.

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [a]The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510405, Guangdong, China [b]Department of Integrated Traditional Chinese & Western Medicine, Xiangya Hospital, Central South University, Changsha 410008, Hunan, China [c]Guangzhou University of Chinese Medicine, Guangzhou 510405, Guangdong, China [d]Department of The Spleen and Stomach, Qingyuan Traditional Chinese Medicine Hospital, Qingyuan 511500, Guangdong, China [e]University of Chinese Academy of Sciences-Shenzhen Hospital, Shenzhen, Guangdong, China [f]Hospital of Traditional Chinese Medicine of Zhongshan, Zhongshan 528400, China [g]Science and Technology Innovation Center, Guangzhou University of Chinese Medicine, Guangzhou 510405, Guangdong, China [h]Department of Gastroenterology, Hainan Provincial Hospital of Traditional Chinese Medicine, Haikou, Hainan, China
出处:
ISSN:

关键词: TP53 Mutation Gastric cancer Immune Prognosis

摘要:
Increasing evidence indicates that TP53 mutation impacts the patients' prognosis by regulating the gastric cancer (GC) immunophenotype. An immune prognostic signature (IPS) was constructed based on TP53 status. The effects of the IPS on the immune microenvironment of GC were analyzed. We also constructed a nomogram integrating the IPS and other clinical factors. An IPS was constructed in the TCGA cohort and validated in the meta-GEO cohort. TP53 mutation resulted in the downregulation of the immune response in GC. Concretely, high-risk patients were characterized by increased monocyte, macrophage M0 and T cell follicular helper infiltration; increased stromal score, ESTIMATE score and immune score; higher TIM3 and BTLA expression; and decreased dendritic cell and T cell CD4 memory-activated infiltration and tumor purity. The nomogram also showed good predictive performance. These results suggest that the IPS is an effective prognostic indicator for GC patients, which might provide a theoretical foundation for immunotherapy. Copyright © 2020. Published by Elsevier Inc.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2019]版:
大类 | 3 区 生物
小类 | 3 区 生物工程与应用微生物 3 区 遗传学
最新[2025]版:
大类 | 2 区 生物学
小类 | 2 区 生物工程与应用微生物 3 区 遗传学
JCR分区:
出版当年[2018]版:
Q2 BIOTECHNOLOGY & APPLIED MICROBIOLOGY Q2 GENETICS & HEREDITY
最新[2023]版:
Q2 BIOTECHNOLOGY & APPLIED MICROBIOLOGY Q2 GENETICS & HEREDITY

影响因子: 最新[2023版] 最新五年平均 出版当年[2018版] 出版当年五年平均 出版前一年[2017版] 出版后一年[2019版]

第一作者:
第一作者机构: [a]The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510405, Guangdong, China [b]Department of Integrated Traditional Chinese & Western Medicine, Xiangya Hospital, Central South University, Changsha 410008, Hunan, China
通讯作者:
通讯机构: [a]The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510405, Guangdong, China [*1]The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510405, Guangdong, China.
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:2018 今日访问量:0 总访问量:645 更新日期:2024-07-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 广东省中医院 技术支持:重庆聚合科技有限公司 地址:广州市越秀区大德路111号